Amid the chaos of the Trump administration’s haphazard job cuts and a mass exodus of leadership, the Food and Drug Administration is experiencing a slowdown of drug reviews and approvals, according to an analysis reported by Stat News. An assessment of metrics by RBC Capital Markets analysts found that FDA drug approvals dropped 14 percentage...